Synapse - Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations Journal Article

Authors:	Lin, R. J.; Ho, C.; Hilden, P. D.; Barker, J. N.; Giralt, S. A.; Hamlin, P. A.; Jakubowski, A. A.; Castro-Malaspina, H. R.; Robinson, K. S.; Papadopoulos, E. B.; Perales, M. A.; Sauter, C. S.
Article Title:	Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations
Abstract:	TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60–88] and 61% (95% CI 43–75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively. Importantly, there is no significant difference among patients with and without TP53 alterations, suggesting for the first time a beneficial treatment modality for these high-risk patients. © 2018 British Society for Haematology and John Wiley & Sons Ltd
Keywords:	mantle cell lymphoma; tp53; allogeneic hematopoietic cell transplant
Journal Title:	British Journal of Haematology
Volume:	184
Issue:	6
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2019-03-11
Start Page:	1006
End Page:	1010
Language:	English
DOI:	10.1111/bjh.15721
PUBMED:	30537212
PROVIDER:	scopus
PMCID:	PMC6399037
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058217795&doi=10.1111%2fbjh.15721&partnerID=40&md5=85ce473aa143bfd0abc0bd0b3ff4d34c
Notes:	Article -- Export Date: 1 April 2019 -- Source: Scopus